{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:21:28Z","timestamp":1790623288033,"version":"4.1.0"},"reference-count":178,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cystic Fibrosis Foundation","award":["SWIATE24A0-MPI"],"award-info":[{"award-number":["SWIATE24A0-MPI"]}]},{"name":"Cystic Fibrosis Foundation","award":["SKOPEL24A0-MPI"],"award-info":[{"award-number":["SKOPEL24A0-MPI"]}]},{"name":"Cystic Fibrosis Foundation","award":["HARRIS24A0-MPI"],"award-info":[{"award-number":["HARRIS24A0-MPI"]}]},{"name":"Cystic Fibrosis Foundation","award":["R01HL144539"],"award-info":[{"award-number":["R01HL144539"]}]},{"name":"Cystic Fibrosis Foundation","award":["P50DK096373-11"],"award-info":[{"award-number":["P50DK096373-11"]}]},{"name":"Cystic Fibrosis Foundation","award":["#7-22-ICTSPM-19\/GR100086"],"award-info":[{"award-number":["#7-22-ICTSPM-19\/GR100086"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SWIATE24A0-MPI"],"award-info":[{"award-number":["SWIATE24A0-MPI"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SKOPEL24A0-MPI"],"award-info":[{"award-number":["SKOPEL24A0-MPI"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HARRIS24A0-MPI"],"award-info":[{"award-number":["HARRIS24A0-MPI"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL144539"],"award-info":[{"award-number":["R01HL144539"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50DK096373-11"],"award-info":[{"award-number":["P50DK096373-11"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["#7-22-ICTSPM-19\/GR100086"],"award-info":[{"award-number":["#7-22-ICTSPM-19\/GR100086"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["SWIATE24A0-MPI"],"award-info":[{"award-number":["SWIATE24A0-MPI"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["SKOPEL24A0-MPI"],"award-info":[{"award-number":["SKOPEL24A0-MPI"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["HARRIS24A0-MPI"],"award-info":[{"award-number":["HARRIS24A0-MPI"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["R01HL144539"],"award-info":[{"award-number":["R01HL144539"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["P50DK096373-11"],"award-info":[{"award-number":["P50DK096373-11"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["#7-22-ICTSPM-19\/GR100086"],"award-info":[{"award-number":["#7-22-ICTSPM-19\/GR100086"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a significant comorbidity that is increasingly linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes, yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary extracellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease management in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.<\/jats:p>","DOI":"10.3390\/jcm14155585","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T12:15:40Z","timestamp":1754568940000},"page":"5585","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5190-7022","authenticated-orcid":false,"given":"Hayrettin","family":"Yavuz","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, VA 22903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu Ballav","family":"Goswami","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Lebanon, NH 03756, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Erdbr\u00fcgger","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0875-4750","authenticated-orcid":false,"given":"William Thomas","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sladjana","family":"Skopelja-Gardner","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Lebanon, NH 03756, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Graber","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dartmouth Geisel School of Medicine, Lebanon, NH 03756, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Swiatecka-Urban","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, VA 22903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: Basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Animal Model. Exp. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_3","first-page":"100829","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1164\/rccm.201108-1554ED","article-title":"Chronic kidney disease: A new morbidity of cystic fibrosis or an old morbidity of diabetes mellitus?","volume":"184","author":"Schechter","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_5","first-page":"694","article-title":"Characteristics of US Individuals With Cystic Fibrosis and ESRD: SA-PO324","volume":"33","author":"Stevanovic","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hart, M., Kumar, M., Goswami, H.B., Harris, W.T., Skopelja-Gardner, S., and Swiatecka-Urban, A. (2025). Cystic fibrosis-related kidney disease-emerging morbidity and disease modifier. Pediatr. Nephrol., Epub ahead of print.","DOI":"10.1007\/s00467-025-06715-3"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nowakowski, A.C.H. (2018). Cystic Fibrosis Kidney Disease: 10 Tips for Clinicians. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00242"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"ref_9","first-page":"e1912","article-title":"Evaluation of the Risk for Acute Kidney Injury in Adult Cystic Fibrosis Patients Receiving Concomitant Vancomycin and Tobramycin","volume":"9","author":"Muirhead","year":"2017","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40635-024-00672-1","article-title":"Advancements in understanding the mechanisms of lung-kidney crosstalk","volume":"12","author":"Mendes","year":"2024","journal-title":"Intensive Care Med. Exp."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3121\/cmr.2015.1282","article-title":"Hypoxia: The Force that Drives Chronic Kidney Disease","volume":"14","author":"Fu","year":"2016","journal-title":"Clin. Med. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneph.2012.280","article-title":"Chronic kidney disease following acute kidney injury-risk and outcomes","volume":"9","author":"Leung","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.1073\/pnas.88.20.9262","article-title":"Immunocytochemical localization of the cystic fibrosis gene product CFTR","volume":"88","author":"Crawford","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","first-page":"F1038","article-title":"Both the wild type and a functional isoform of CFTR are expressed in kidney","volume":"270","author":"Morales","year":"1996","journal-title":"Am. J. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, J.T., Wang, Y., Chen, J.J., Zhang, X.H., Dong, J.D., Tsang, L.L., Huang, X.R., Cai, Z., Lan, H.Y., and Jiang, X.H. (2017). Defective CFTR leads to aberrant \u03b2-catenin activation and kidney fibrosis. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-05435-5"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1164\/rccm.201105-0932OC","article-title":"Risk factors for chronic kidney disease in adults with cystic fibrosis","volume":"184","author":"Quon","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2017.11.001","article-title":"Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis","volume":"17","author":"Berg","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ki.2009.544","article-title":"Better nephrology for mice\u2014And man","volume":"77","author":"Matthew","year":"2010","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1681\/ASN.2008060617","article-title":"Reduced production of creatinine limits its use as marker of kidney injury in sepsis","volume":"20","author":"Doi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","first-page":"352","article-title":"Measurement of creatinine by Jaffe\u2019s reaction--determination of concentration of sodium hydroxide required for maximum color development in standard, urine and protein free filtrate of serum","volume":"40","author":"Toora","year":"2002","journal-title":"Indian. J. Exp. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/clinchem\/21.10.1422","article-title":"Kinetic enzymatic method for determining serum creatinine","volume":"21","author":"Moss","year":"1975","journal-title":"Clin. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5858\/2005-129-297-CMSOTA","article-title":"Creatinine measurement: State of the art in accuracy and interlaboratory harmonization","volume":"129","author":"Miller","year":"2005","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"F1116","DOI":"10.1152\/ajprenal.00366.2003","article-title":"A simplified method for HPLC determination of creatinine in mouse serum","volume":"286","author":"Yuen","year":"2004","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1039\/C7DT00018A","article-title":"Dimensional heterostructures of 1D CdS\/2D ZnIn(2)S(4) composited with 2D graphene: Designed synthesis and superior photocatalytic performance","volume":"46","author":"Tian","year":"2017","journal-title":"Dalton Trans."},{"key":"ref_28","unstructured":"Gounden, V., Bhatt, H., and Jialal, I. (2025, June 02). Renal Function Tests, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507821\/."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mizdrak, M., Kumri\u0107, M., Kurir, T.T., and Bo\u017ei\u0107, J. (2022). Emerging Biomarkers for Early Detection of Chronic Kidney Disease. J. Pers. Med., 12.","DOI":"10.3390\/jpm12040548"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100600","DOI":"10.1016\/j.xkme.2023.100600","article-title":"Estimated GFR With Cystatin C and Creatinine in Clinical Practice: A Retrospective Cohort Study","volume":"5","author":"Gottlieb","year":"2023","journal-title":"Kidney Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2023.06.008","article-title":"Performance of GFR Estimating Equations in Young Adults","volume":"83","author":"Inker","year":"2024","journal-title":"Am. J. Kidney Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","article-title":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease","volume":"99","author":"Pierce","year":"2021","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2008.07.004","article-title":"GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis","volume":"8","author":"Beringer","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2710.2008.00932.x","article-title":"Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin","volume":"33","author":"Halacova","year":"2008","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2054358119899312","DOI":"10.1177\/2054358119899312","article-title":"Estimation of GFR in Patients With Cystic Fibrosis: A Cross-Sectional Study","volume":"7","author":"Wallace","year":"2020","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e003245","DOI":"10.1161\/JAHA.116.003245","article-title":"Urine Albumin\/Creatinine Ratio Below 30 mg\/g is a Predictor of Incident Hypertension and Cardiovascular Mortality","volume":"5","author":"Sung","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/oem.2009.054122","article-title":"The threshold level of urinary cadmium associated with increased urinary excretion of retinol-binding protein and beta 2-microglobulin: A re-assessment in a large cohort of nickel-cadmium battery workers","volume":"68","author":"Chaumont","year":"2011","journal-title":"Occup. Environ. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1258\/acb.2011.011158","article-title":"Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand","volume":"49","author":"Tate","year":"2012","journal-title":"Ann. Clin. Biochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/1523-1747.ep12500079","article-title":"A low-molecular-weight soluble protein from bovine lingual epithelium. II. Purification and characterization","volume":"79","author":"Telser","year":"1982","journal-title":"J. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/biot.201400072","article-title":"Isoforms of wild type proteins often appear as low molecular weight bands on SDS-PAGE","volume":"9","author":"Zhang","year":"2014","journal-title":"Biotechnol. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.34067\/KID.0002492022","article-title":"Fractional Excretion of Sodium and Urea are Useful Tools in the Evaluation of AKI: PRO","volume":"4","author":"Hamadah","year":"2023","journal-title":"Kidney360"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wo\u0142yniec, W., Kasprowicz, K., Rita-Tkachenko, P., Renke, M., and Ratkowski, W. (2019). Biochemical Markers of Renal Hypoperfusion, Hemoconcentration, and Proteinuria after Extreme Physical Exercise. Medicina, 55.","DOI":"10.3390\/medicina55050154"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jcf.2024.12.007","article-title":"Lung-kidney axis in cystic fibrosis: Early urinary markers of kidney injury correlate with neutrophil activation and worse lung function","volume":"24","author":"Rosner","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"ref_49","unstructured":"Downes, K.J., and Goldstein, S.L. (2016). Biomarkers in Kidney Disease, Springer."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00467-013-2712-4","article-title":"Electrolyte abnormalities in cystic fibrosis: Systematic review of the literature","volume":"29","author":"Fossali","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"ref_51","first-page":"369","article-title":"Systemic AA amyloidosis: Epidemiology, diagnosis, and management","volume":"6","author":"Costa","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Allinovi, M., Trivioli, G., Gaudio, C., L\u2019Imperio, V., Rauf, M.U., and Gillmore, J.D. (2025). The evolving spectrum of kidney amyloidosis: Advances in diagnosis, typing and treatment. Nephrol. Dial. Transplant., gfaf042.","DOI":"10.1093\/ndt\/gfaf042"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.autrev.2015.05.009","article-title":"Diagnosis and monitoring of IgA nephropathy: The role of biomarkers as an alternative to renal biopsy","volume":"14","author":"Moresco","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4239\/wjd.v1.i2.48","article-title":"Renal function in diabetic nephropathy","volume":"1","author":"Dabla","year":"2010","journal-title":"World J. Diabetes"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrneph.2010.71","article-title":"Drug-induced acute interstitial nephritis","volume":"6","author":"Perazella","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00467-016-3394-5","article-title":"Tubulointerstitial nephritis: Diagnosis, treatment, and monitoring","volume":"32","author":"Joyce","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"ref_58","unstructured":"Wong, E.C., Dietzen, D.J., Bennett, M.J., and Haymond, S. (2021). Biochemical and Molecular Basis of Pediatric Disease, Academic Press. [5th ed.]."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Fan, H., Hui, L., Yan, X., Hou, W., Bai, E., Wang, L., and Yu, X. (2020). Serum 25 hydroxyvitamin D levels and affecting factors among preconception fertile women. BMC Women\u2019s Health, 20.","DOI":"10.1186\/s12905-020-01018-1"},{"key":"ref_60","first-page":"e81778","article-title":"Idiopathic Hypercalciuria: A Comprehensive Review of Clinical Insights and Management Strategies","volume":"17","author":"Meher","year":"2025","journal-title":"Cureus"},{"key":"ref_61","unstructured":"Kronenberg, H.M., Polonsky, K.S., Larsen, P.R., and Melmed, S. (2016). Williams Textbook of Endocrinology, Elsevier. [13th ed.]."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2215\/CJN.12191213","article-title":"Biomarkers of AKI: A review of mechanistic relevance and potential therapeutic implications","volume":"10","author":"Alge","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bcp.12282","article-title":"Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development","volume":"77","author":"Moerland","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","article-title":"Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury","volume":"62","author":"Han","year":"2002","journal-title":"Kidney Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00365510802145059","article-title":"Kidney Injury Molecule-1 (KIM-1): A specific and sensitive biomarker of kidney injury","volume":"241","author":"Bonventre","year":"2008","journal-title":"Scand. J. Clin. Lab. Investig. Suppl."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1093\/ndt\/gfp010","article-title":"Kidney injury molecule-1 (KIM-1): A urinary biomarker and much more","volume":"24","author":"Bonventre","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40620-014-0113-9","article-title":"Urine interleukin-18 in prediction of acute kidney injury: A systemic review and meta-analysis","volume":"28","author":"Lin","year":"2015","journal-title":"J. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2174\/1389203717666160909125004","article-title":"The Update of NGAL in Acute Kidney Injury","volume":"18","author":"Shang","year":"2017","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Huang, F., Zeng, Y., Lv, L., Chen, Y., Yan, Y., Luo, L., Pan, R., Jiang, J., and Wei, X. (2023). Predictive value of urinary cell cycle arrest biomarkers for all cause-acute kidney injury: A meta-analysis. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-33233-9"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11606-008-0850-3","article-title":"High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine","volume":"24","author":"Duru","year":"2009","journal-title":"J. Gen. Intern. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1681\/ASN.2008070669","article-title":"Creatinine kinetics and the definition of acute kidney injury","volume":"20","author":"Waikar","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Seki, M., Nakayama, M., Sakoh, T., Yoshitomi, R., Fukui, A., Katafuchi, E., Tsuda, S., Nakano, T., Tsuruya, K., and Kitazono, T. (2019). Blood urea nitrogen is independently associated with renal outcomes in Japanese patients with stage 3-5 chronic kidney disease: A prospective observational study. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1306-1"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/ndt\/gfac045","article-title":"Urea levels and cardiovascular disease in patients with chronic kidney disease","volume":"38","author":"Laville","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/14737159.2020.1768849","article-title":"Cystatin C as a biomarker of chronic kidney disease: Latest developments","volume":"20","author":"Benoit","year":"2020","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-147-1-200707030-00004","article-title":"Cystatin C as a risk factor for outcomes in chronic kidney disease","volume":"147","author":"Menon","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5001\/omj.2012.23","article-title":"Estimated Glomerular Filtration Rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice","volume":"27","year":"2012","journal-title":"Oman Med. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.trre.2011.10.002","article-title":"Proteinuria: Detection and role in native renal disease progression","volume":"26","author":"Gorriz","year":"2012","journal-title":"Transplant. Rev."},{"key":"ref_78","first-page":"1219","article-title":"Understanding kidney injury molecule 1: A novel immune factor in kidney pathophysiology","volume":"11","author":"Song","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_79","first-page":"e23563","article-title":"Association between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease","volume":"7","author":"Sedighi","year":"2015","journal-title":"Nephrourol. Mon."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Argyropoulos, C.P., Chen, S.S., Ng, Y.-H., Roumelioti, M.-E., Shaffi, K., Singh, P.P., and Tzamaloukas, A.H. (2017). Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00073"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2215\/CJN.03530708","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ndt\/gfn486","article-title":"IL-18 is involved in vascular injury in end-stage renal disease patients","volume":"24","author":"Porazko","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cyto.2013.05.023","article-title":"Elevated interleukin-12 and interleukin-18 in chronic kidney disease are not associated with arterial stiffness","volume":"64","author":"Yong","year":"2013","journal-title":"Cytokine"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lee, B.T., Ahmed, F.A., Hamm, L.L., Teran, F.J., Chen, C.-S., Liu, Y., Shah, K., Rifai, N., Batuman, V., and Simon, E.E. (2015). Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol., 16.","DOI":"10.1186\/s12882-015-0068-7"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"F1231","DOI":"10.1152\/ajprenal.00557.2012","article-title":"Tumor necrosis factor-\u03b1: Regulation of renal function and blood pressure","volume":"304","author":"Ramseyer","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.kint.2019.01.035","article-title":"Low levels of urinary epidermal growth factor predict chronic kidney disease progression in children","volume":"96","author":"Azukaitis","year":"2019","journal-title":"Kidney Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.kint.2023.08.007","article-title":"The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events","volume":"104","author":"Menez","year":"2023","journal-title":"Kidney Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/bcp.13988","article-title":"Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study","volume":"85","author":"Uges","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcf.2010.03.007","article-title":"Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis","volume":"9","author":"Guy","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jcf.2023.10.021","article-title":"Identification of prognostic biomarkers for antibiotic associated nephrotoxicity in cystic fibrosis","volume":"23","author":"Hart","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41581-022-00586-9","article-title":"Extracellular vesicles in kidney disease","volume":"18","author":"Grange","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13287-015-0150-x","article-title":"Role of extracellular RNA-carrying vesicles in cell differentiation and reprogramming","volume":"6","author":"Quesenberry","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000526842","article-title":"Extracellular Vesicles in Acute Kidney Injury","volume":"147","author":"Yavuz","year":"2023","journal-title":"Nephron"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","article-title":"Current knowledge on exosome biogenesis and release","volume":"75","author":"Hessvik","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1681\/ASN.2020071035","article-title":"Large-Scale Proteomic Assessment of Urinary Extracellular Vesicles Highlights Their Reliability in Reflecting Protein Changes in the Kidney","volume":"32","author":"Wu","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"13368","DOI":"10.1073\/pnas.0403453101","article-title":"Identification and proteomic profiling of exosomes in human urine","volume":"101","author":"Pisitkun","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.34067\/KID.0001892022","article-title":"Extracellular Vesicles in Kidney Diseases: Moving Forward","volume":"4","author":"Erdbrugger","year":"2023","journal-title":"Kidney360"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1016\/j.transproceed.2013.08.079","article-title":"Urinary exosomes as a source of kidney dysfunction biomarker in renal transplantation","volume":"45","author":"Alvarez","year":"2013","journal-title":"Transplant. Proc."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Panich, T., Chancharoenthana, W., Somparn, P., Issara-Amphorn, J., Hirankarn, N., and Leelahavanichkul, A. (2017). Urinary exosomal activating transcriptional factor 3 as the early diagnostic biomarker for sepsis-induced acute kidney injury. BMC Nephrol., 18.","DOI":"10.1186\/s12882-016-0415-3"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Svenningsen, P., Maslauskiene, R., Palarasah, Y., Bumblyte, I.A., and Tepel, M. (2024). Urinary Extracellular Vesicles for Non-Invasive Quantification of Principal Cell Damage in Kidney Transplant Recipients. Biomolecules, 14.","DOI":"10.3390\/biom14091124"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Miller, D., Eagle-Hemming, B., Sheikh, S., Joel-David, L., Adebayo, A., Lai, F.Y., Roman, M., Kumar, T., Aujla, H., and Murphy, G.J. (2022). Urinary extracellular vesicles and micro-RNA as markers of acute kidney injury after cardiac surgery. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-13849-z"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"F486","DOI":"10.1152\/ajprenal.00404.2019","article-title":"Acute and chronic glomerular damage is associated with reduced CD133 expression in urinary extracellular vesicles","volume":"318","author":"Dimuccio","year":"2020","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ckj\/sfu136","article-title":"Extracellular vesicles in the urine: Markers and mediators of tissue damage and regeneration","volume":"8","author":"Ranghino","year":"2015","journal-title":"Clin. Kidney J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e012584","DOI":"10.1161\/JAHA.119.012584","article-title":"Senescent Kidney Cells in Hypertensive Patients Release Urinary Extracellular Vesicles","volume":"8","author":"Santelli","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"105416","DOI":"10.1016\/j.isci.2022.105416","article-title":"Urinary extracellular vesicles signature for diagnosis of kidney disease","volume":"25","author":"Takizawa","year":"2022","journal-title":"iScience"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.202209-1653OC","article-title":"Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole-Genome Analysis of 7,840 Patients","volume":"207","author":"Zhou","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Sepahzad, A., Morris-Rosendahl, D.J., and Davies, J.C. (2021). Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine. Genes, 12.","DOI":"10.3390\/genes12040562"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Leggatt, G.P., Seaby, E.G., Veighey, K., Gast, C., Gilbert, R.D., and Ennis, S. (2023). A Role for Genetic Modifiers in Tubulointerstitial Kidney Diseases. Genes, 14.","DOI":"10.3390\/genes14081582"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Deltas, C., Papagregoriou, G., Louka, S.F., Malatras, A., Flinter, F., Gale, D.P., Gear, S., Gross, O., Hoefele, J., and Lennon, R. (2023). Genetic Modifiers of Mendelian Monogenic Collagen IV Nephropathies in Humans and Mice. Genes, 14, (9).","DOI":"10.3390\/genes14091686"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Trojan, T., Alejandre Alcazar, M.A., Fink, G., Thomassen, J.C., Maessenhausen, M.V., Rietschel, E., Schneider, P.M., and van Koningsbruggen-Rietschel, S. (2022). The effect of TGF-beta(1) polymorphisms on pulmonary disease progression in patients with cystic fibrosis. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-01977-1"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1164\/rccm.201704-0732OC","article-title":"MicroRNA-145 Antagonism Reverses TGF-beta Inhibition of F508del CFTR Correction in Airway Epithelia","volume":"197","author":"Kabir","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Sun, H., Harris, W.T., Kortyka, S., Kotha, K., Ostmann, A.J., Rezayat, A., Sridharan, A., Sanders, Y., Naren, A.P., and Clancy, J.P. (2014). Tgf-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106842"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1681\/ASN.2018040437","article-title":"Mechanism of Fibrosis in HNF1B-Related Autosomal Dominant Tubulointerstitial Kidney Disease","volume":"29","author":"Chan","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/ndt\/gfp079","article-title":"Genetic variation in the transforming growth factor-beta1 gene is associated with susceptibility to IgA nephropathy","volume":"24","author":"Vuong","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"F1135","DOI":"10.1152\/ajprenal.00366.2020","article-title":"Overexpression of TGF-beta1 induces renal fibrosis and accelerates the decline in kidney function in polycystic kidney disease","volume":"319","author":"Zhang","year":"2020","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Tang, P.C.-T., Chan, A.S.-W., Zhang, C.-B., Garc\u00eda C\u00f3rdoba, C.A., Zhang, Y.-Y., To, K.-F., Leung, K.-T., Lan, H.-Y., and Tang, P.M.-K. (2021). TGF-beta1 Signaling: Immune Dynamics of Chronic Kidney Diseases. Front. Med., 8.","DOI":"10.3389\/fmed.2021.628519"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Marson, F.A., Bertuzzo, C.S., Hortencio, T.D.R., Ribeiro, J.D., Bonadia, L.C., and Ribeiro, A.F. (2012). The ACE gene D\/I polymorphism as a modulator of severity of cystic fibrosis. BMC Pulm. Med., 12.","DOI":"10.1186\/1471-2466-12-41"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41467-023-35862-0","article-title":"SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation","volume":"14","author":"Bezzerri","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Baldassarri, M., Zguro, K., Tomati, V., Pastorino, C., Fava, F., Croci, S., Bruttini, M., Picchiotti, N., Furini, S., and Pedemonte, N. (2022). Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes. Cells, 11.","DOI":"10.3390\/cells11244096"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/0886022X.2016.1160247","article-title":"Does angiotensin-converting enzyme-1 (ACE-1) gene polymorphism lead to chronic kidney disease among hypertensive patients?","volume":"38","author":"Sarkar","year":"2016","journal-title":"Ren. Fail."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0272-6386(98)70045-9","article-title":"ACE gene polymorphism in childhood IgA nephropathy: Association with clinicopathologic findings","volume":"31","author":"Tanaka","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1172\/JCI6861","article-title":"Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis","volume":"104","author":"Garred","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/ajt.15160","article-title":"Impact of MBL2 gene polymorphisms on the risk of infection in solid organ transplant recipients: A systematic review and meta-analysis","volume":"19","author":"Lora","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Sanchez-Dominguez, C.N., Reyes-Lopez, M.A., Bustamante, A., Cerda-Flores, R.M., Villalobos-Torres, M.d.C., Gallardo-Blanco, H.L., Rojas-Martinez, A., Martinez-Rodriguez, H.G., Barrera-Salda\u00f1a, H.A., and Ortiz-Lopez, R. (2014). The tumor necrosis factor alpha (-308 A\/G) polymorphism is associated with cystic fibrosis in Mexican patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090945"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1681\/ASN.2017010076","article-title":"Mannose-Binding Lectin Levels Could Predict Prognosis in IgA Nephropathy","volume":"28","author":"Guo","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: The lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.21037\/atm-20-1073","article-title":"Mannose-binding lectin activation is associated with the progression of diabetic nephropathy in type 2 diabetes mellitus patients","volume":"8","author":"Cai","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_128","first-page":"S191","article-title":"Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency","volume":"13","author":"McElvaney","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1183\/09031936.00118408","article-title":"Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency","volume":"34","author":"Brand","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.ejhg.5200623","article-title":"An alpha1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis","volume":"9","author":"Henry","year":"2001","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1165\/rcmb.2002-0271OC","article-title":"Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease","volume":"29","author":"Frangolias","year":"2003","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1183\/09031936.98.11040873","article-title":"Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease","volume":"11","author":"Mahadeva","year":"1998","journal-title":"Eur. Respir. J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ppul.1950180104","article-title":"Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508","volume":"18","author":"Doring","year":"1994","journal-title":"Pediatr. Pulmonol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1034\/j.1399-0004.2002.620413.x","article-title":"Analysis of the two common alpha-1-antitrypsin deficiency alleles PiMS and PiMZ as modifiers of Pseudomonas aeruginosa susceptibility in cystic fibrosis","volume":"62","author":"Meyer","year":"2002","journal-title":"Clin. Genet."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Zager, R.A., Johnson, A.C., and Frostad, K.B. (2014). Rapid renal alpha-1 antitrypsin gene induction in experimental and clinical acute kidney injury. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098380"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.21037\/jtd.2019.12.17","article-title":"Serum alpha 1-antitrypsin predicts severe acute kidney injury after cardiac surgery","volume":"11","author":"Du","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ki.1993.186","article-title":"Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis","volume":"43","author":"Esnault","year":"1993","journal-title":"Kidney Int."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e240288","DOI":"10.1136\/bcr-2020-240288","article-title":"Nephrotic syndrome secondary to alpha-1 antitrypsin deficiency","volume":"14","author":"Santos","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1067\/mai.2002.129704","article-title":"Effect of beta-adrenergic agonists on mucociliary clearance","volume":"110","author":"Bennett","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/FPC.0b013e3280119349","article-title":"Beta-2-adrenergic receptor polymorphisms in cystic fibrosis","volume":"17","author":"Steagall","year":"2007","journal-title":"Pharmacogenet Genom."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1183\/13993003.01661-2015","article-title":"beta2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis","volume":"48","author":"Vijftigschild","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/nep.13584","article-title":"Beta2-adrenergic receptor in kidney biology: A current prospective","volume":"24","author":"Arif","year":"2019","journal-title":"Nephrology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"R575","DOI":"10.1152\/ajpregu.00287.2020","article-title":"beta(2)-Adrenergic receptor agonism as a therapeutic strategy for kidney disease","volume":"320","author":"Kamiar","year":"2021","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/thx.2004.025262","article-title":"Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype","volume":"60","author":"Yarden","year":"2005","journal-title":"Thorax"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0161-5890(99)00127-3","article-title":"Polymorphism of the human TNF-alpha promoter--random variation or functional diversity?","volume":"36","author":"Allen","year":"1999","journal-title":"Mol. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000351684","article-title":"Tumor necrosis factor alpha promoter polymorphism and severity of acute kidney injury","volume":"123","author":"Susantitaphong","year":"2013","journal-title":"Nephron Clin. Pract."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000074930","article-title":"Polymorphism of immunomodulatory cytokine genes: Implications in acute renal failure","volume":"22","author":"Jaber","year":"2004","journal-title":"Blood Purif."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nm1783","article-title":"A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1093\/ndt\/gfn533","article-title":"Does TNF-alpha enhance cystogenesis in ADPKD?","volume":"23","author":"Pirson","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jcf.2007.11.004","article-title":"Association of interleukin-10 gene haplotypes with Pseudomonas aeruginosa airway colonization in cystic fibrosis","volume":"7","author":"Tesse","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1086\/429964","article-title":"Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis","volume":"191","author":"Brouard","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5500\/wjt.v3.i4.91","article-title":"Role of IL-10 in the progression of kidney disease","volume":"3","author":"Sinuani","year":"2013","journal-title":"World J. Transplant."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Mu, H., Zheng, Q., and Hao, L. (2021). IL-10 -1082 A\/G polymorphism is related with the risk and clinical characteristics of acute kidney injury: A case-control study. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02410-1"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1523-1755.2004.00730.x","article-title":"Association of interleukin-10 gene G-1082A polymorphism with the progression of primary glomerulonephritis","volume":"66","author":"Bantis","year":"2004","journal-title":"Kidney Int."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ppul.10455","article-title":"NO pathway in CF and non-CF children","volume":"37","author":"Wooldridge","year":"2004","journal-title":"Pediatr. Pulmonol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"L374","DOI":"10.1152\/ajplung.00039.2004","article-title":"Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epithelium","volume":"287","author":"Zheng","year":"2004","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1006\/niox.2001.0408","article-title":"Nasal nitric oxide levels in cystic fibrosis patients are associated with a neuronal NO synthase (NOS1) gene polymorphism","volume":"6","author":"Grasemann","year":"2002","journal-title":"Nitric Oxide"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1164\/ajrccm.162.6.2003106","article-title":"Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene","volume":"162","author":"Grasemann","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/thorax.2003.006718","article-title":"Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis","volume":"59","author":"Texereau","year":"2004","journal-title":"Thorax"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1164\/rccm.200202-155OC","article-title":"Endothelial nitric oxide synthase variants in cystic fibrosis lung disease","volume":"167","author":"Grasemann","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MNH.0b013e32834d54ca","article-title":"Nitric oxide synthase derangements and hypertension in kidney disease","volume":"21","author":"Baylis","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1590\/2175-8239-jbn-3824","article-title":"NOS3 Polymorphisms and Chronic Kidney Disease","volume":"40","author":"Medina","year":"2018","journal-title":"J. Bras. Nefrol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/2175-8239-jbn-2021-0089","article-title":"NOS3 gene intron 4 a\/b polymorphism is associated with ESRD in autosomal dominant polycystic kidney disease patients","volume":"44","author":"Padhi","year":"2022","journal-title":"J. Bras. Nefrol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/thx.53.12.1018","article-title":"Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis","volume":"53","author":"Hull","year":"1998","journal-title":"Thorax"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00008571-200405000-00004","article-title":"Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis","volume":"14","author":"Flamant","year":"2004","journal-title":"Pharmacogenetics"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/0886022X.2016.1214054","article-title":"Association between GSTM1, GSTT1, and GSTP1 variants and the risk of end stage renal disease","volume":"38","author":"Nomani","year":"2016","journal-title":"Ren. Fail."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/j.ajkd.2021.10.007","article-title":"Association of GSTM1 Deletion With Progression of CKD in Children: Findings From the Chronic Kidney Disease in Children (CKiD) Study","volume":"80","author":"Levy","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00424.2007","article-title":"Nitric oxide deficiency in chronic kidney disease","volume":"294","author":"Baylis","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"F993","DOI":"10.1152\/ajprenal.00450.2018","article-title":"Loss of miR-17~92 results in dysregulation of Cftr in nephron progenitors","volume":"316","author":"Phua","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"McHugh, D.R., Steele, M.S., Valerio, D.M., Miron, A., Mann, R.J., LePage, D.F., Conlon, R.A., Cotton, C.U., Drumm, M.L., and Hodges, C.A. (2018). A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199573"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"G528","DOI":"10.1152\/ajpgi.00052.2011","article-title":"Cystic fibrosis growth retardation is not correlated with loss of Cftr in the intestinal epithelium","volume":"301","author":"Hodges","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"L944","DOI":"10.1152\/ajplung.00387.2003","article-title":"Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice","volume":"287","author":"Schluchter","year":"2004","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/rccm.202002-0369OC","article-title":"Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR","volume":"202","author":"Birket","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e97199","DOI":"10.1172\/jci.insight.97199","article-title":"Development of an airway mucus defect in the cystic fibrosis rat","volume":"3","author":"Birket","year":"2018","journal-title":"JCI Insight"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1172\/JCI43052","article-title":"Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis","volume":"120","author":"Sun","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Delrue, C., De Bruyne, S., and Speeckaert, M.M. (2024). Application of Machine Learning in Chronic Kidney Disease: Current Status and Future Prospects. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030568"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5585\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:25:33Z","timestamp":1760034333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":178,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155585"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155585","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}